Researchers have revealed that a clinical trial where cancer cells were targeted by modified version of the measles virus has shown positive early results.
The trial suggests that when the modified virus was given to patients with multiple myeloma, a rare cancer affecting white blood cells in bone marrow specifically they reduced the tumor, the Verge reported.
The researchers revealed that this is the first time, through an intravenous injection; they were able to eliminate cancer in a human subject using the virus. The modified virus was able to target the tumors itself and even treat affected bone marrow.
Dr. Stephen J. Russell, the study's lead author said that they believe this particular treatment approach can be the single shot cure.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app